1.19
price down icon4.03%   -0.05
after-market Handel nachbörslich: 1.18 -0.01 -0.84%
loading
Schlusskurs vom Vortag:
$1.24
Offen:
$1.18
24-Stunden-Volumen:
859.00K
Relative Volume:
0.73
Marktkapitalisierung:
$60.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-0.7169
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
-26.09%
1M Leistung:
-28.74%
6M Leistung:
-72.39%
1J Leistung:
-92.76%
1-Tages-Spanne:
Value
$1.14
$1.23
1-Wochen-Bereich:
Value
$1.14
$1.615
52-Wochen-Spanne:
Value
$1.14
$19.04

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Firmenname
Cabaletta Bio Inc
Name
Telefon
(267) 759-3100
Name
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Name
Mitarbeiter
0
Name
Twitter
@CabalettaBio
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
CABA's Discussions on Twitter

Vergleichen Sie CABA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CABA
Cabaletta Bio Inc
1.19 60.38M 0 -67.68M -54.24M -1.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Herabstufung Evercore ISI Outperform → In-line
2024-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2024-10-10 Eingeleitet UBS Buy
2024-02-05 Eingeleitet Jefferies Buy
2023-11-29 Eingeleitet William Blair Outperform
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-10-19 Eingeleitet Stifel Buy
2023-09-05 Eingeleitet Citigroup Buy
2023-07-18 Eingeleitet Guggenheim Buy
2023-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-08-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-06-30 Eingeleitet Mizuho Buy
2021-01-08 Eingeleitet Chardan Capital Markets Buy
2020-10-13 Eingeleitet H.C. Wainwright Buy
2019-11-19 Eingeleitet Cowen Outperform
2019-11-19 Eingeleitet Evercore ISI Outperform
2019-11-19 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten

pulisher
12:58 PM

Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat

12:58 PM
pulisher
10:39 AM

Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire

10:39 AM
pulisher
10:15 AM

Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com

10:15 AM
pulisher
05:02 AM

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World

05:02 AM
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Lowered to $7.00 at UBS Group - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com

Apr 01, 2025
pulisher
Apr 01, 2025

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Mar 31, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia

Mar 26, 2025
pulisher
Mar 24, 2025

Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register

Mar 24, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat

Mar 22, 2025
pulisher
Mar 20, 2025

Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News

Mar 20, 2025
pulisher
Mar 19, 2025

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Breakthrough: Cellares Successfully Automates Multi-Batch CAR T Production for 260,000 Patients - Stock Titan

Mar 19, 2025
pulisher
Mar 17, 2025

Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView

Mar 17, 2025
pulisher
Mar 16, 2025

Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat

Mar 16, 2025
pulisher
Mar 12, 2025

Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat

Mar 12, 2025
pulisher
Mar 09, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 06, 2025
pulisher
Mar 02, 2025

Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN

Mar 02, 2025
pulisher
Mar 01, 2025

Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com Australia

Mar 01, 2025

Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):